TELOMIR PHARMACEUTICALS, INC.

Telomir Pharmaceuticals announced preclinical findings on Telomir-1's copper-binding potential for Wilson's disease, offering a safer alternative to current treatments. The company is advancing Telomir-1 for Type 2 diabetes and age-related diseases, with IND-enabling studies planned for 2025 and clinical trials by mid-2026. Telomir also aims to secure INAD for pets and explore dual applications in human and veterinary medicine.

Telomir Pharmaceuticals announced Telomir-1's copper binding capabilities, expanding its potential for Wilson's disease treatment. The company discontinued its osteoarthritis study in dogs due to ethical concerns and plans IND-enabling safety studies for Q2 2025, targeting IND submission by Q4 2025, with first-in-human trials expected in H1 2026.

Telomir Pharmaceuticals raised $1M at $7/share, a 20% premium, in a no-warrant, restricted common stock deal. The company reported breakthrough preclinical results for Telomir-1, showing age-reversal benefits and potential Type 2 diabetes treatment. Telomir-1 targets aging and disease causes like oxidative stress and telomere shortening, with research expanding into Progeria, Alzheimer's, cancer, Wilson Disease, and osteoarthritis.

Telomir Pharmaceuticals announced preclinical results for Telomir-1, showing age-reversal effects in aging model organisms, improved mobility, reduced biological aging, and increased lifespan. The study used C. elegans and plans to investigate Telomir-1's potential in treating progeria.

Three drug startups raised over $700 million in IPOs, marking a significant event in 2024's biotech market. Bicara Therapeutics secured $315 million, Zenas BioPharma $225 million, and MBX Biosciences $163 million. Despite challenges, these companies have drugs in later stages of testing, reflecting a trend of later-stage IPOs amidst market uncertainties.

A groundbreaking age reversal study on dogs, involving a drug that lengthens telomere caps, has shown remarkable results, including a dog's cancer disappearing. The study, led by Dr. Christopher Chapman and Dr. Michael Roizen, suggests potential for human application, aiming for longer, healthier lives. Human trials for osteo-arthritis are planned for 2025.